New Data Puts FAST BioMedical ‘On the 15-Yard Line’

Posted: Updated:
FAST employees manufacture the injectable, which works with a device, to measure blood volume. FAST employees manufacture the injectable, which works with a device, to measure blood volume.

Doctors in critical hospital settings make judgement calls—sometimes life or death decisions—based on information, but there’s one stat that has been notoriously difficult to obtain, says Carmel-based startup FAST BioMedical. Doctors are clamoring for a better way to determine a patient’s blood volume, an important measurement that can dictate treatment in the critical care setting. Recently validated by clinical trial data that’s “as good or better than we ever thought it could be” and publications in national journals, FAST Biomedical is confident its technology will soon save lives.

Blood volume, also referred to as fluid status, is the amount of blood flowing through a patient’s intravascular system. Blood volume measurements are especially critical for patients with heart failure or sepsis, a life-threatening condition. The Centers for Disease Control and Prevention (CDC) says one in three patients who die in a hospital has sepsis, and the condition kills about 270,000 Americans each year. Blood volume is also vital information for patients with cardiorenal disfunction. 

“I’ve heard enough stories from clinicians where they’re doing the best they can with some pretty crude metrics, and in some of these very complicated patients, it just goes the wrong way,” says FAST BioMedical Chief Executive Officer Joe Muldoon.

FAST BioMedical’s technology combines an injectable and device to provide precise measurements for blood volume and kidney function. Doctors inject patients with a small dose of a proprietary fluorescent solution, then take timed blood samples. The samples are processed in a device that measures the concentration of the fluorescent marker in the blood and runs it through algorithms to calculate the blood volume within 45 minutes.

Recent results from a Phase 2B clinical trial were “so good” they’ve been published in peer-reviewed medical journals and are “enabling a lot of conversations,” says Muldoon.

“We were able to show in our trial that we could take all different kinds of patients, administer fluid to them, and we could literally follow it with our technology—what that fluid did to their overall blood or fluid level,” says Muldoon. “To our knowledge, nobody has ever been able to demonstrate that before. It followed it very precisely; the technology was accurate and reproduceable, and it was over different types of patients. That was dramatic.”

It’s a milestone for the company, says Muldoon, marking one of its most significant achievements “in our entire decade of work.”

“People are, literally, coming out of the woodwork and calling us,” says Muldoon. “The data’s really good; it shows that not only is [the technology] accurate and safe, but we can measure things nobody’s ever been able to measure.”

With a long list of Indiana investors, the startup has raised $31 million, and is planning Series B funding next; Muldoon notes raising capital is especially difficult “if you’re not a therapeutic” (drug).

“If you’re pre-commercial in the med tech space, it’s just a challenging environment to raise capital,” says Muldoon. “It feels like we’ve turned the corner with this data; now we’re taking more incoming calls than having outgoing calls, but it’s still hard.”

While there is an existing method to measure blood volume, it uses an expensive radioactive nucleotide; the method has not seen commercial adoption and has been limited mostly to research. Muldoon says doctors want a clinically viable method to determine blood volume that’s easier to use, cheaper and focused on patients, “and our technology gives them that.” The startup believes it could be on the market in about three years.  

“I think our technology is going to improve the lives of patients and even save some lives,” says Muldoon. “It’s good to be on the 15-yard line, but we don’t celebrate until we’re in the endzone.”

Muldoon says the company has tweaked its market approach to lower the cost of adoption for hospitals.
Muldoon says the startup has brought on new key investors who are experienced in injectable and device combination products.
  • Perspectives

    • Baby Boomers Are Impacting the Building Industry

      There are currently 78 million baby boomers in the U.S., making up 25% of the population and controlling 67% ($28 trillion) of the country’s wealth, according to the Living In Place Institute. AARP says 90% of people surveyed want to remain as long as possible in their homes. The majority of those 65 and older remodel their home to make it safer and accessible. In fact, 45% of all remodeling work is being done for people over the age of 65. With this amount of data supporting...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Hub & Spoke Aims to Fuel 'Purpose and Passion'

      The co-founder of a $16 million mixed-use development in Fishers says the project aims to have the biggest social impact possible. Officials broke ground Tuesday on Hub & Spoke, which will include a design center, coworking space and makerspace when completed. David Decker says the project is the first of its kind in the nation and seeks to help people find their purpose and passion and tie that into their vocation. In an interview with Inside INdiana Business Reporter...

    • (Photo Courtesy: Roche Diagnostics)

      Roche VP on List of Influential Women Executives

      An executive with Roche Diagnostics has joined an exclusive list of prominent and influential women, including Oprah Winfrey and Serena Williams.  Cindy Carlisle, Vice President of Human Resources at Roche Indy, was named to Savoy Magazine’s 2019 Most Influential Women in Corporate America. 

    • The facility could be build within the River Ridge Commerce Center.

      Jeffersonville Being Considered for CBD Plant

      California-based Layn USA could soon establish operations in southern Indiana. One Southern Indiana, the economic development organization and chamber of commerce for Clark and Floyd counties, says the company has signed a purchase and sales agreement with the River Ridge Development Authority for a proposed $52 million CBD manufacturing facility. The project, the company says, would have the capacity to process a minimum of 5,000 tons of hemp biomass each year. As part of the...

    • Rendering courtesy of Two EEs Winery

      Two-EE's Winery to Adopt New Age Policy

      Two-EE's Winery in Huntington has announced it will adopt a new age policy begining in August. Our partners at WPTA-TV report the winery will no longer allow people aged under 21 to visit the establishment due to ongoing problems with unsupervised or misbehaving children. 

    • New Mixed-Use Development Planned for Fishers

      A new mixed-use development is coming to Fishers. Thompson Thrift Retail Group has announced the development of The Station, an office building that is part of an overall project that includes a 150-room hotel, a future retail pad along 116th Street and nearly 40 3-story townhomes.